pp 1-13 | Cite as

Evidence and Function Relevance of Native DOR–MOR Heteromers

  • Catherine M. Cahill
  • Edmund Ong
Part of the Handbook of Experimental Pharmacology book series


Opioid receptors are the sites of action for morphine and most other clinically used opioid drugs. Abundant evidence now demonstrates that different opioid receptor types can physically associate to form heteromers. Owing to their constituent monomers’ involvement in analgesia, mu/delta opioid receptor (M/DOR) heteromers have been a particular focus of attention. Understandings of the physiological relevance and indisputable proof of M/DOR formation in vivo are still evolving. This aspect of the field has been slow to progress in large part by the limitations of most available experimental models; recently however, promising progress is being made. As a result, the long-repeated promise of opioid receptor heteromers as selective therapeutic targets is now being realized.


Analgesia Antinociception Delta Dimer Heterodimer Heteromer Mu Opiate Opioid Pain Receptor interaction Receptor trafficking 


  1. Abdelhamid EE, Sultana M, Portoghese PS, Takemori AE (1991) Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J Pharmacol Exp Ther 258(1):299–303Google Scholar
  2. Abul-Husn NS, Sutak M, Milne B, Jhamandas K (2007) Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of mu- and delta-opioid receptor antagonists. Br J Pharmacol 151(6):877–887Google Scholar
  3. Ananthan S et al (2012) 14-Alkoxy- and 14-acyloxypyridomorphinans: mu agonist/delta antagonist opioid analgesics with diminished tolerance and dependence side effects. J Med Chem 55(19):8350–8363Google Scholar
  4. Bardo MT, Hughes RA (1979) Exposure to a nonfunctional hot plate as a factor in the assessment of morphine-induced analgesia and analgesic tolerance in rats. Pharmacol Biochem Behav 10(4):481–485Google Scholar
  5. Beaudry H, Gendron L, Moron JA (2015) Implication of delta opioid receptor subtype 2 but not delta opioid receptor subtype 1 in the development of morphine analgesic tolerance in a rat model of chronic inflammatory pain. Eur J Neurosci 41(7):901–907Google Scholar
  6. Breslin HJ et al (2012) Identification of a dual delta OR antagonist/mu OR agonist as a potential therapeutic for diarrhea-predominant Irritable Bowel Syndrome (IBS-d). Bioorg Med Chem Lett 22(14):4869–4872Google Scholar
  7. Cahill CM et al (2001) Prolonged morphine treatment targets delta opioid receptors to neuronal plasma membranes and enhances delta-mediated antinociception. J Neurosci 21(19):7598–7607Google Scholar
  8. Cahill CM, Morinville A, Hoffert C, O’Donnell D, Beaudet A (2003) Up-regulation and trafficking of delta opioid receptor in a model of chronic inflammation: implications for pain control. Pain 101:199–208Google Scholar
  9. Cahill CM, Holdridge SV, Morinville A (2007) Trafficking of delta-opioid receptors and other G-protein-coupled receptors: implications for pain and analgesia. Trends Pharmacol Sci 28(1):23–31Google Scholar
  10. Cai J et al (2014) Endomorphin analogues with mixed mu-opioid (MOP) receptor agonism/delta-opioid (DOP) receptor antagonism and lacking beta-arrestin2 recruitment activity. Bioorg Med Chem 22(7):2208–2219Google Scholar
  11. Chefer VI, Shippenberg TS (2009) Augmentation of morphine-induced sensitization but reduction in morphine tolerance and reward in delta-opioid receptor knockout mice. Neuropsychopharmacology 34(4):887–898Google Scholar
  12. Chen H-J et al (2012) Disruption of delta-opioid receptor phosphorylation at threonine 161 attenuates morphine tolerance in rats with CFA-induced inflammatory hypersensitivity. Neurosci Bull 28(2):182–192Google Scholar
  13. Chung PCS et al (2015) Delta opioid receptors expressed in forebrain GABAergic neurons are responsible for SNC80-induced seizures. Behav Brain Res 278:429–434Google Scholar
  14. Costantino CM, Gomes I, Stockton SD, Lim MP, Devi LA (2012) Opioid receptor heteromers in analgesia. Expert Rev Mol Med 14(April):e9Google Scholar
  15. Daniels DJ et al (2005) Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc Natl Acad Sci U S A 102(52):19208–19213Google Scholar
  16. Décaillot FM, Rozenfeld R, Gupta A, Devi LA (2008) Cell surface targeting of mu-delta opioid receptor heterodimers by RTP4. Proc Natl Acad Sci U S A 105(41):16045–16050Google Scholar
  17. Egan TM, North RA (1981) Both mu and delta opiate receptors exist on the same neuron. Science 214(4523):923–924Google Scholar
  18. Erbs E et al (2015) A mu-delta opioid receptor brain atlas reveals neuronal co-occurrence in subcortical networks. Brain Struct Funct 220(2):677–702Google Scholar
  19. Espejo EF, Mir D (1994) Differential effects of weekly and daily exposure to the hot plate on the rat’s behavior. Physiol Behav 55(6):1157–1162Google Scholar
  20. Fox-Threlkeld JE et al (1994) Identification of mechanisms and sites of actions of mu and delta opioid receptor activation in the canine intestine. J Pharmacol Exp Ther 268(2):689–700Google Scholar
  21. Fujita W et al (2014) Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers. Biochem Pharmacol 92(3):448–456Google Scholar
  22. Fundytus ME, Schiller PW, Shapiro M, Weltrowska G, Coderre TJ (1995) Attenuation of morphine tolerance and dependence with the highly selective delta-opioid receptor antagonist TIPP[psi]. Eur J Pharmacol 286(1):105–108Google Scholar
  23. Gardon O et al (2014) Expression of mu opioid receptor in dorsal diencephalic conduction system: new insights for the medial habenula. Neuroscience 277:595–609Google Scholar
  24. Gendron L, Pintar JE, Chavkin C (2007) Essential role of mu opioid receptor in the regulation of delta opioid receptor-mediated antihyperalgesia. Neuroscience 150(4):807–817Google Scholar
  25. Gendron L, Cahill CM, Von Zastrow M, Schiller PW, Pineyro G (2016) Molecular pharmacology of δ-opioid receptors. Pharmacol Rev 68:631–700Google Scholar
  26. Gilron I, Watson CPN, Cahill CM, Moulin DE (2006) Neuropathic pain: a practical guide for the clinician. CMAJ 175(3):265–275Google Scholar
  27. Gomes I et al (2000) Heterodimerization of mu and delta opioid receptors: a role in opiate synergy. J Neurosci 20(22):RC110Google Scholar
  28. Gomes I et al (2004) A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci U S A 101(14):5135–5139Google Scholar
  29. Gomes I et al (2013) Identification of a μ-δ opioid receptor heteromer-biased agonist with antinociceptive activity. Proc Natl Acad Sci U S A 110(29):12072–12077Google Scholar
  30. Gomes I, Gupta A, Bushlin I, Devi LA (2014) Antibodies to probe endogenous G protein-coupled receptor heteromer expression, regulation, and function. Front Pharmacol 5:268Google Scholar
  31. Gomes I et al (2016) G protein-coupled receptor heteromers. Annu Rev Pharmacol Toxicol 56:403–425Google Scholar
  32. Gupta A et al (2010) Increased abundance of opioid receptor heteromers after chronic morphine administration. Sci Signal 3(131):ra54Google Scholar
  33. Hack SP, Bagley EE, Chieng BCH, Christie MJ (2005) Induction of delta-opioid receptor function in the midbrain after chronic morphine treatment. J Neurosci 25(12):3192–3198Google Scholar
  34. He S-Q et al (2011) Facilitation of mu-opioid receptor activity by preventing delta-opioid receptor-mediated codegradation. Neuron 69(1):120–131Google Scholar
  35. Jordan BA, Devi LA (1999) G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399(6737):697–700Google Scholar
  36. Kest B, Lee CE, McLemore GL, Inturrisi CE (1996) An antisense oligodeoxynucleotide to the delta opioid receptor (DOR-1) inhibits morphine tolerance and acute dependence in mice. Brain Res Bull 39(3):185–188Google Scholar
  37. Law P-Y et al (2005) Heterodimerization of mu- and delta-opioid receptors occurs at the cell surface only and requires receptor-G protein interactions. J Biol Chem 280(12):11152–11164Google Scholar
  38. Le Merrer J, Rezai X, Scherrer G, Becker JAJ, Kieffer BL (2013) Impaired hippocampus-dependent and facilitated striatum-dependent behaviors in mice lacking the delta opioid receptor. Neuropsychopharmacology 38(6):1050–1059Google Scholar
  39. Lenard NR, Daniels DJ, Portoghese PS, Roerig SC (2007) Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores. Eur J Pharmacol 566(1–3):75–82Google Scholar
  40. Levio S, Cash BD (2017) The place of eluxadoline in the management of irritable bowel syndrome with diarrhea. Ther Adv Gastroenterol 10(9):715–725Google Scholar
  41. Lucido AL, Morinville A, Gendron L, Stroh T, Beaudet A (2005) Prolonged morphine treatment selectively increases membrane recruitment of delta-opioid receptors in mouse basal ganglia. J Mol Neurosci 25(3):207–214Google Scholar
  42. Margolis EB, Fujita W, Devi LA, Fields HL (2017) Two delta opioid receptor subtypes are functional in single ventral tegmental area neurons, and can interact with the mu opioid receptor. Neuropharmacology 123:420–432Google Scholar
  43. Mattia A, Vanderah T, Mosberg HI, Porreca F (1991) Lack of antinociceptive cross-tolerance between [D-Pen2, D-Pen5]enkephalin and [D-Ala2]deltorphin II in mice: evidence for delta receptor subtypes. J Pharmacol Exp Ther 258(2):583–587Google Scholar
  44. Morinville A, Cahill CM, Kieffer B, Collier B, Beaudet A (2004a) Mu-opioid receptor knockout prevents changes in delta-opioid receptor trafficking induced by chronic inflammatory pain. Pain 109(3):266–273Google Scholar
  45. Morinville A et al (2004b) Morphine-induced changes in delta opioid receptor trafficking are linked to somatosensory processing in the rat spinal cord. J Neurosci 24:5549–5559Google Scholar
  46. Nakama-Kitamura M, Doe N (2003) The influence of contextual cue on antinociceptive tolerance and facilitation of memory with morphine. J Pharmacol Sci 92(3):237–244Google Scholar
  47. Pinello C et al (2010) Characterization of an agonist probe for opioid receptor mu 1 (OPRM1)-opioid receptor delta 1 (OPRD1) heterodimerization. National Center for Biotechnology Information, BethesdaGoogle Scholar
  48. Poole DP et al (2011) Localization and regulation of fluorescently labeled delta opioid receptor, expressed in enteric neurons of mice. Gastroenterology 141(3):982–991.e18Google Scholar
  49. Porreca F, Heyman JS, Mosberg HI, Omnaas JR, Vaught JL (1987) Role of mu and delta receptors in the supraspinal and spinal analgesic effects of [D-Pen2, D-Pen5]enkephalin in the mouse. J Pharmacol Exp Ther 241(2):393–400Google Scholar
  50. Provasi D, Boz MB, Johnston JM, Filizola M (2015) Preferred supramolecular organization and dimer interfaces of opioid receptors from simulated self-association. PLoS Comput Biol 11(3):e1004148Google Scholar
  51. Rothman RB et al (1992) Probing the opioid receptor complex with (+)-trans-SUPERFIT. II. Evidence that mu ligands are noncompetitive inhibitors of the delta cx opioid peptide binding site. Peptides 13(6):1137–1143Google Scholar
  52. Rozenfeld R, Devi LA (2007) Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers. FASEB J 21(10):2455–2465Google Scholar
  53. Scherrer G et al (2006) Knockin mice expressing fluorescent delta-opioid receptors uncover G protein-coupled receptor dynamics in vivo. Proc Natl Acad Sci U S A 103(25):9691–9696Google Scholar
  54. Scherrer G et al (2009) Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. Cell 137(6):1148–1159Google Scholar
  55. Siuda ER, Carr R 3rd, Rominger DH, Violin JD (2017) Biased mu-opioid receptor ligands: a promising new generation of pain therapeutics. Curr Opin Pharmacol 32:77–84Google Scholar
  56. Spahn V, Stein C (2017) Targeting delta opioid receptors for pain treatment: drugs in phase I and II clinical development. Expert Opin Investig Drugs 26(2):155–160Google Scholar
  57. Stockton SD, Devi LA (2012) Functional relevance of μ-δ opioid receptor heteromerization: a role in novel signaling and implications for the treatment of addiction disorders: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend 121(3):167–172Google Scholar
  58. van Rijn RM, Whistler JL (2009) The delta(1) opioid receptor is a heterodimer that opposes the actions of the delta(2) receptor on alcohol intake. Biol Psychiatry 66(8):777–784Google Scholar
  59. Waldhoer M et al (2005) A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc Natl Acad Sci U S A 102(25):9050–9055Google Scholar
  60. Williams D, Devi LA (2010) Escorts take the lead molecular chaperones as therapeutic targets. Prog Mol Biol Transl Sci 91:121–149Google Scholar
  61. Xie W-Y et al (2009) Disruption of Cdk5-associated phosphorylation of residue threonine-161 of the delta-opioid receptor: impaired receptor function and attenuated morphine antinociceptive tolerance. J Neurosci 29(11):3551–3564Google Scholar
  62. Yekkirala AS, Kalyuzhny AE, Portoghese PS (2013) An immunocytochemical-derived correlate for evaluating the bridging of heteromeric mu-delta opioid protomers by bivalent ligands. ACS Chem Biol 8(7):1412–1416Google Scholar
  63. Zhu Y et al (1999) Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron 24(1):243–252Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Psychiatry and Biobehavioral Sciences, Hatos Center for NeuropharmacologySemel Institute for Neuroscience and Human Behavior, University of California Los AngelesLos AngelesUSA
  2. 2.Department of AnesthesiologyDuke UniversityDurhamUSA

Personalised recommendations